Last updated on February 2018

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy


Brief description of study

Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.

Detailed Study Description

XELOX

  • Xeloda, 1000mg/ bid, day 1-15, every 3 weeks
  • Oxaliplatin 130mg/, day 1, every 3 weeks Until disease progression, patient's refusal or up to 8 cycles (maximum).

Clinical Study Identifier: NCT02350686

Find a site near you

Start Over

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.